What it’s for
- Blood-glucose management in type 2 diabetes
A prescription medicine that slows the digestion of carbohydrates.
Purpose, evidence and practical considerations.
It reduces post-meal glucose and modestly lowers HbA1c. Those effects do not establish a longevity benefit in people without diabetes or cardiovascular-event prevention in every population.
Confidence: strong
Flatulence, diarrhea and abdominal discomfort are common and dose-related. It is contraindicated with inflammatory bowel disease, colonic ulceration, intestinal obstruction risk, cirrhosis or diabetic ketoacidosis. When hypoglycemia occurs with insulin or a secretagogue, treat with glucose rather than sucrose because acarbose delays sucrose digestion. Liver enzymes and renal function require clinical consideration.
Acarbose competitively inhibits intestinal alpha-glucosidases, delaying carbohydrate digestion and reducing the post-meal glucose rise. It acts mainly in the gut and has not been shown to slow human aging.
Regulatory status: prescription-only in the United States (FDA approved Precose 6 September 1995, NDA 020482) and the European Union (Glucobay / generics). Not OTC. Not a supplement. No aging indication anywhere this review checked.
How people use it, with their schedules, context and original sources.
200 mg twice daily; the same page also says 400 mg daily · twice daily
blunt post-meal glucose
Dose and schedule patterns reported in public protocols; these are observations, not prescribing advice. Private and hidden usage is excluded.
These share a protocol with this intervention. This does not establish that they work together or are suitable alternatives.